Brought to you by 
Selecta licenses next-gen immunotoxin from NCI's Center for Cancer Research
05 May 2017
Executive Summary
The Center for Cancer Research, part of the National Cancer Institute, granted Selecta Biosciences Inc. exclusive and nonexclusive global rights to patents pertaining to anti-mesothelin targeted immunotoxins for the treatment of mesothelin-expressing cancers. The deal includes LMB100, a next-generation immunotoxin.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Selecta licenses next-gen immunotoxin from NCI's Center for Cancer Research
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice